ReviewCNS drugs2007
Overview on pathophysiology and newer approaches to treatment of peripheral neuropathies.
Review in CNS drugs, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Neuroprotective Effect of Natural Products on Peripheral Nerve Degeneration: A Systematic Review.Neurochemical research · 2016Pooled it
- Frequency of persistent tooth pain after root canal therapy: a systematic review and meta-analysis.Journal of endodontics · 2010Pooled it
- Postoperative pain after one-visit root-canal treatment on teeth with vital pulps: comparison of three different obturation techniques.Medicina oral, patologia oral y cirugia bucal · 2012Trial
- Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: a randomized, double-blind, comparative study.Clinical drug investigation · 2008Trial
- Large fiber contribution to symptoms in chemotherapy-induced peripheral neuropathy in cancer survivors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Article
- Review
- Neuroprotective Effect ofNutrients · 2020Article
- Bottlenecks in the development of topical analgesics: molecule, formulation, dose-finding, and phase III design.Journal of pain research · 2017Review
- Neurotoxic effects of iron overload under high glucose concentration.Neural regeneration research · 2013Article
- High association of IL-4 gene intron 3 VNTR polymorphism with diabetic peripheral neuropathy.Journal of molecular neuroscience : MN · 2013Article
- Ketogenic diets and thermal pain: dissociation of hypoalgesia, elevated ketones, and lowered glucose in rats.The journal of pain · 2013Article
- Purines and neuronal excitability: links to the ketogenic diet.Epilepsy research · 2012Review
- Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom control.Current clinical pharmacology · 2011Review
- Role of Drp1, a key mitochondrial fission protein, in neuropathic pain.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2011Article
- "Doctor, why does my tooth still hurt"?Northwest dentistryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral neuropathies are extremely heterogeneous nosological entities. One of the most common symptoms is pain, the underlying mechanisms of which are numerous and complex. Inflammation, reparative processes, and anatomical and gene expression alterations lead to chronic pain, the persistence of which is sustained by peripheral and central sensitisation mechanisms. Treatment of peripheral neuropathies is targeted to its symptomatic and aetiological features. For pain relief, several types of drugs may be used, notably antidepressants (e.g. tricyclic antidepressants, selective serotonin reuptake inhibitors, and both serotonin and noradrenaline [norepinephrine] reuptake inhibitors), antiepileptic drugs (e.g. carbamazepine, phenytoin, lamotrigine, valproic acid, gabapentin, topiramate and pregabalin), NSAIDs and opioid analgesics. Aetiological therapy is aimed at modifying the pathophysiological mechanisms underlying the neuropathy, some of which are common in different neuropathic conditions. Certain drugs are known to exert more than one action on different pathophysiological mechanisms. This is the case with acetyl-L-carnitine (ALC), which can be considered both a symptomatic therapy that can be used in any kind of painful neuropathy, and an aetiological therapy, at least in diabetic neuropathy and neuropathies induced by nucleoside reverse transcriptase inhibitors and cancer chemotherapeutic agents. ALC acts via several mechanisms, inducing regeneration of injured nerve fibres, reducing oxidative stress, supporting DNA synthesis in mitochondria, and enhancing nerve growth factor concentrations in neurons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.